Comorbidities and breast cancer survival: a report from the Shanghai Breast Cancer Survival Study

[1]  A. Ording,et al.  Comorbidity and survival of Danish breast cancer patients from 2000–2011: a population-based cohort study , 2013, Clinical epidemiology.

[2]  M. Holmes,et al.  Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality , 2012, Breast Cancer Research.

[3]  J. Adolfsson,et al.  Impact of comorbidity on management and mortality in women diagnosed with breast cancer , 2012, Breast Cancer Research and Treatment.

[4]  R. Hiatt,et al.  Prognostic Impact of Comorbidity among Long-Term Breast Cancer Survivors: Results from the LACE Study , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[5]  S. Dalton,et al.  Comorbidity and survival after early breast cancer. A review. , 2012, Critical reviews in oncology/hematology.

[6]  S. Dalton,et al.  Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990–2008 , 2012, Breast Cancer Research and Treatment.

[7]  D. Khemasuwan,et al.  Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins , 2011, Cancer investigation.

[8]  M. Trudeau,et al.  Stage at Diagnosis and Comorbidity Influence Breast Cancer Survival in First Nations Women in Ontario, Canada , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[9]  T. Byers,et al.  The influence of comorbidities on overall survival among older women diagnosed with breast cancer. , 2011, Journal of the National Cancer Institute.

[10]  W. McCaskill-Stevens,et al.  Comorbidities in the aging breast cancer population: are current assessments leading to improved outcomes? , 2011, Journal of the National Cancer Institute.

[11]  G. Hortobagyi,et al.  Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  K. Bennett,et al.  Beta blockers and breast cancer mortality: a population- based study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Byers,et al.  Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study , 2011, Breast Cancer Research.

[14]  X. Shu,et al.  Concordance of self-reported and medical chart information on cancer diagnosis and treatment , 2011, BMC medical research methodology.

[15]  P. Ganz,et al.  Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort , 2011, Breast Cancer Research and Treatment.

[16]  I. Ellis,et al.  Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival , 2010, Oncotarget.

[17]  Frederick Wolfe,et al.  Rheumatoid arthritis , 2010, The Lancet.

[18]  C. Rock,et al.  Medical comorbidities predict mortality in women with a history of early stage breast cancer , 2010, Breast Cancer Research and Treatment.

[19]  X. Shu,et al.  Soy food intake and breast cancer survival. , 2009, JAMA.

[20]  A. McTiernan,et al.  Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer , 2009, Journal of cancer survivorship : research and practice.

[21]  B. Zinman,et al.  The impact of diabetes on survival following breast cancer , 2008, Breast Cancer Research and Treatment.

[22]  C. Johansen,et al.  Influence of socioeconomic factors on survival after breast cancer—A nationwide cohort study of women diagnosed with breast cancer in Denmark 1983–1999 , 2007, International journal of cancer.

[23]  Valery E P P Lemmens,et al.  Comorbidity in older surgical cancer patients: influence on patient care and outcome. , 2007, European journal of cancer.

[24]  H. Sørensen,et al.  Comorbidity and survival of Danish breast cancer patients from 1995 to 2005 , 2007, British Journal of Cancer.

[25]  J. Coebergh,et al.  Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. , 2005, European journal of cancer.

[26]  G. Nagel,et al.  The impact of comorbidity on the survival of postmenopausal women with breast cancer , 2004, Journal of Cancer Research and Clinical Oncology.

[27]  Edward L Spitznagel,et al.  Prognostic importance of comorbidity in a hospital-based cancer registry. , 2004, JAMA.

[28]  J. Coebergh,et al.  Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients , 2004, British Journal of Cancer.

[29]  G. Anderson,et al.  The Growing Burden of Chronic Disease in America , 2004, Public health reports.

[30]  G. Maskarinec,et al.  Influences of ethnicity, treatment, and comorbidity on breast cancer survival in Hawaii. , 2003, Journal of clinical epidemiology.

[31]  R Yancik,et al.  Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. , 2001, JAMA.

[32]  B E Ainsworth,et al.  Compendium of physical activities: an update of activity codes and MET intensities. , 2000, Medicine and science in sports and exercise.

[33]  D. Kleinbaum.  Survival Analysis: A Self-Learning Text , 1997 .

[34]  R. Hiatt,et al.  Comorbidity and breast cancer survival: a comparison between black and white women. , 1996, Annals of epidemiology.

[35]  W. Satariano,et al.  The Effect of Comorbidity on 3-Year Survival of Women with Primary Breast Cancer , 1994, Annals of Internal Medicine.

[36]  M. Roizen.  Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients , 2010 .

[37]  E L Korn,et al.  Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. , 1997, American journal of epidemiology.

[38]  D W Bates,et al.  Can comorbidity be measured by questionnaire rather than medical record review? , 1996, Medical care.